Cleveland, OH, United States of America

Barry E Nall

This inventor holds 1 USPTO granted patent. Top assignee: Chiesi Farmaceutici S.p.a.. Active years: 2018.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Barry E Nall: Innovator in Micronized Drug Preparation

Introduction

Barry E Nall is a notable inventor based in Cleveland, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of micronized particles for drug delivery. His innovative work focuses on enhancing the stability and efficacy of antimuscarinic compounds.

Latest Patents

Barry E Nall holds a patent titled "Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation." This patent describes a method for creating crystalline micronized particulate of a glycopyrronium salt through hydrodynamic cavitation. The resulting drug particles are noted for their physical stability concerning agglomeration and/or aggregation during storage. He has 1 patent to his name.

Career Highlights

Barry is currently associated with Chiesi Farmaceutici S.p.a., a company known for its commitment to developing innovative pharmaceutical solutions. His work at Chiesi has allowed him to focus on advancing drug formulation techniques that improve patient outcomes.

Collaborations

Throughout his career, Barry has collaborated with esteemed colleagues, including Timothy J Rouse and Stephen P Davanzo. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Barry E Nall's contributions to the field of pharmaceuticals, particularly in the preparation of micronized drug particles, highlight his role as an innovator. His work continues to influence the development of effective drug delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…